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1. Supplementary Methods 15 
 16 
Ascertainment of families for the asthma VU study 17 
The families who participate in the asthma VU study are a sample of a larger number of Dutch twin 18 
families who participate in an ongoing survey study of health-related behavior (1,2). The first two surveys 19 
on health and lifestyle were sent in 1991 and 1993 to adolescent twins and their parents. Subjects for the 20 
asthma study were selected from families who returned the first 2 questionnaires. 21 
 Twin families were recruited by asking all city councils in The Netherlands for addresses of twins 22 
aged 13-22 years. An initial positive response was received from 252 city councils that supplied 3859 23 
addresses; 177 addresses were available from other sources. After contacting these 4036 families by letter, 24 
2375 twin families indicated that they were willing to complete a questionnaire on health and lifestyle and 25 
1700 families returned these questionnaires in 1991. Data from 3 families were entered twice by mistake, 26 
leaving a total of 1697 families. In 1993 a second questionnaire was mailed to the 4036 families that had 27 
been contacted before and to 1987 new families. Additional addresses of new twin families were obtained 28 
from city councils which had reacted positively to our request, but were not able to furnish addresses in 29 
time for the first wave of data collection. The new addresses included several of the larger cities in the 30 
Netherlands. At the second measurement occasion we obtained questionnaires from 1974 families; 959 31 
families participated for the second time; 877 families came from the new addresses; 138 families were 32 
contacted before in 1991 but had not responded at the time. In total we have studied 2712 families 33 
measured at two different occasions, with 959 families participating twice. 34 
 Age of the twins was between 12-25 years. The mean age of the twins at the first measurement 35 
occasion was 17.7 years (SD = 2.3), 4% of this sample was younger than 14 years and 7% was 21 years 36 
or older. The mean age of the twins that participated for the first time in 1993 was 16.0 years (SD = 2.7). 37 
In this group 29% of the sample was younger than 14 years and 7% was 21 years or older. Zygosity of the 38 
twins was determined by DNA fingerprinting.  39 
 The questionnaires contained items about asthma, bronchitis and allergies, as well as questions 40 
about drinking, smoking, socio-economic status, religion and a number of personality factors. 41 































































These questions were answered by the twin pair and by both their biological parents. The prevalence of 42 
asthma and allergies in twins based on first questionnaire was: 43 
 44 
  Asthma Allergy Correlation Asthma-allergy 45 
Boys 13%   14%  .51 46 
 Girls 10%  17%  .52 47 
 48 
The tetrachoric twin correlations (standard errors) were (see also Supplementary ref. 3): 49 
 50 
 N(pairs) Asthma Allergy 51 
 MZM 243  .77 (.075) .64 (.100) 52 
 DZM 233  .19 (.155) .15 (.148) 53 
 MZF 324  .77 (.072) .43 (.110) 54 
 DZF  300  .44 (.126) .22 (.117) 55 
 DOS  448  .25 (.116) .19 (.095) 56 
 57 
Families were selected to participate in the asthma study if one of the twins or one of their parents 58 
indicated that they had asthma. The selection was also based on age of the twins (older than 18 years). 59 
Selection based on the first questionnaire indicated 146 families that met these criteria. A letter was sent 60 
to these families asking them to participate in the asthma study; 53 families were willing to participate 61 
and of these, 42 were studied in the hospital. The second selection was carried out on the new families 62 
who returned the second questionnaire. Based on the same criteria as before, 57 new families living near 63 
Amsterdam were tested.  64 
 65 
Clinical protocol used in the asthma VU study 66 
Questionnaire administration. The questionnaire is based on the WHO and CARA-TNO-questionnaires. 67 
Both were extensively investigated in the Netherlands. Questions concerned symptoms such as cough, 68 































































periods of bronchitis, wheezing, dyspnoe, attacks of asthma, rhinitis, pneumoniae (doctor diagnosis) and 69 
asthma (doctor diagnosis).  Information about smoking habits, medication, work, and family were 70 
recorded.  Most questions have a good reproducibility (kappa > 0.5). For the present analyses, 71 
participants with a self-reported doctor diagnosis of asthma were considered affected for the Asthma trait.    72 
  73 
Lung function test. FVC and FEV1 are measured with the VMAX22 pneumotachograph of Sensor 74 
Medics. The measurements are according guidelines of the ATS. Twice a day, calibration was carried out 75 
with a calibration pump of 3 ltr and an automatic calibration program. Calibration reports are available. 76 
 77 
Airway methacoline challenge test. The test used the method of tidal breathing for 2 minutes and meets 78 
the guidelines of standardization. After baseline measurements of pulmonary function, individuals inhaled 79 
nebulized NaCl 0.9% from a DEVILLBISS 646 nebulizer (output 0.13 ml/min, flow of 5.5 l/min, 80 
aerosol about 5 micron ). If the decrease in FEV1 was less than 10%, the test was performed. 81 
Sequential aerosols of metacholine was given in concentrations of 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10, 20, 40, 82 
80 and 160 mg/ml. Each concentration was inhaled for 2 minutes, after each challenge FEV1 maneuvers 83 
were performed. The metacholine concentration at which there was a decrease in FEV1 of 20% 84 
(compared to baseline) was taken as the threshold value (PC20m). The determination of PC20m is 85 
calculated by linear interpolation of the last two points of the concentration-dose curve (4).                                                                 86 
For the present analyses, a bronchial hyperresponsiveness (BHR) test was considered positive if the 87 
participant experienced a drop in FEV1 of 20% after the last dose of methacoline given.  88 
 89 
Bronchial Reversibility Test. Following the methacoline challenge test, a bronchial reversibility test with 90 
Salbutamol was performed after FEV1 returned to baseline value (mostly after one hour). Subjects 91 
inhaled four times 200mcg of salbutamol (MDI) through a chamber (volumatic). After 15 minutes FEV1 92 
maneuvers were performed. When there is an improvement of FEV1 of 200 ml or 12%, reversibility is 93 
significant according to ATS criteria. 94 
 95 































































Skin Prick Test. Tests were done to grass, trees, weeds, house dust-mite, other mites, cat, dog, horse, other 96 
animals (rabbit), feathers (birds), Aspergillus fumigatus, Cladosporium herbarum, Alternaria altenarium, 97 
and Candida albicans. The test was considered positive when a response was > 2mm greater than the 98 
negative control. A participant was defined as atopic if one or more of the following criteria were met: (1) 99 
total IgE > 2 SD above normal of the Dutch population; (2) raised (>100 U/l) serum IgE against molds, 100 
cat, grass or English rawweed; or (3) positive skin prick test. 101 
 102 
Measurement of total and specific IgE levels. Total IgE was measured using Phadezym Prist, Pharmacia 103 
ltd. Specific IgE against molds, cat, grass and English rawweed was detected by Pharmacia Cap Sweden. 104 































































2. Supplementary Tables 105 
 106 
Supplementary Table 1. Characteristics of the study participants for the four individual studies. 107 
  AS VU BH TM 
    
  
N individuals 
Genotyped 2493 353 532 2092 
Clinically tested 1703 360 457 660 
Both 1697 353 457 660 
     
  
Clinical characteristics a 
Females, % 54.5 53.3 59.1 51.7 
Mean age, years 28.8 36.1 34.7 12 
Asthma, % 54.7 19.3 58.9 - 
BHR, % 40.0 22.1 26.3 - 
Atopy, % 69.2 41.6 55.1 - 
Dpter, % 56.5 23.8 24.5 - 
Ever smoker, % 30.2 26.9 47.5 - 




offspring N families analysed 
b 
2 3 or more 139 4 0 0 
2 2 146 67 0 152 
2 1 37 6 0 69 
1 3 or more 29 1 0 0 
1 2 66 10 0 98 
1 1 38 1 0 41 
0 3 or more 28 0 0 0 
0 2 146 1 156 17 
0 1 106 9 147 50 
 Total 735 99 303 427 
a Figures are based on individuals that were both genotyped and clinically tested.  108 
b
 Figures consider founders in a family if genotyped, and non-founders if both genotyped and clinically 109 
tested. 110 
AS: QIMR asthma study. VU:  VU University study. BH: Bispebjerg Hospital study. TM: QIMR twin 111 
moles study. BHR: positive bronchial hyperresponsiveness. Dpter: positive skin-prick response to house 112 
dust mite. 113 































































Supplementary Table 2. Details of the QC filters applied to the SNP data. 114 
 Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 
Studies genotyped AS,TM  AS AS AS,VU,BH, others AS,VU,BH, others 









ICOS, ADAM23 ADAM23 
N Sequenom assays 2  1 1 1 1 
           
 SNP Individuals SNP Individuals SNP Individuals SNP Individuals SNP Individuals 
Initial N 39 4662 24 2530 25 2510 21 4638 20 4639 
           
Monomorphic SNP 0 - 1 - 1 - 0 - 1 - 
SNP with call rate 
<0.9 3 - 0 - 3 - 0 - 0 - 
Individuals with call 
rate <0.9 - 501 - 40 - 36 - 91 - 211 
SNP with Mendel 
error rate >0.05 0 - 0 - 0 - 0 - 1 - 
Individuals from 
families with Mendel 
error rate >0.05 - 60 - 164 - 49 - 33  3 
SNP with H-W 
P<0.0001 0 - 1 - 0 - 0 - 0 - 
SNP with MAF<0.01 0 - 2 - 0 - 0 - 0 - 
Individuals from 
other studies - 0 - 0 - 0 - 1177 - 1119 
           
Final N 36 4101 20 2326 21 2425 21 2273 18 2242 
AS: QIMR asthma study. VU:  VU University study. BH: Bispebjerg Hospital study. TM: QIMR twin 115 
moles study. SNP: single nucleotide polymorphism. H-W: Hardy-Weinberg equilibrium test. MAF: minor 116 
allele frequency. 117 































































Supplementary Table 3.  Multivariate association results between four asthma traits and CD28, CTLA4 118 
and ICOS SNPs on chromosome 2q33, for the combined analysis of the AS, VU and BH studies. 119 
Loadingsa Minor allele 









CD28 rs10211663 204271260 1125 2559 1.000 - - - - T 0.08 
CD28 rs1879877 204278245 1127 2566 0.643 - - - - T 0.22 
CD28 rs3181096 204278337 665 1532 0.028 -0.13 -0.88 0.05 0.41 C 0.36 
CD28 rs3181098 204278623 1125 2554 0.452 - - - - A 0.36 
CD28 rs3181100 204280251 1123 2556 0.625 - - - - G 0.40 
CD28 rs3181101 204280279 1121 2550 1.000 - - - - G 0.13 
CD28 rs2140148 204280385 1123 2558 0.520 - - - - C 0.17 
CD28 rs1181388 204284196 666 1539 0.049 0.28 -0.59 0.45 0.86 A 0.13 
CD28 rs3769683 204287042 1125 2557 0.121 - - - - A 0.13 
CD28 rs7425641 204287845 1125 2561 0.333 - - - - T 0.08 
CD28 rs4675363 204298316 1124 2552 0.727 - - - - C 0.26 
CD28 rs3116496 204302757 667 1543 0.084 -0.97 0.23 -0.63 -0.15 C 0.17 
CD28 rs3181113 204310155 1128 2586 0.375 - - - - T 0.03 
CD28 rs6435203 204319440 666 1539 0.192 - - - - G 0.26 
CD28 rs231385 204329736 664 1531 0.187 - - - - A 0.26 
CTLA4 rs231735 204402121 667 1536 0.089 0.51 -0.64 0.53 0.78 G 0.48 
CTLA4 rs926169 204430997 1127 2567 1.000 - - - - T 0.41 
CTLA4 rs231770 204437398 665 1535 0.098 0.79 -0.60 0.59 0.57 T 0.41 
CTLA4 rs5742909 204440592 1125 2566 0.579 - - - - T 0.08 
CTLA4 rs231775 204440959 1124 2561 0.778 - - - - G 0.38 
CTLA4 rs231779 204442732 1127 2566 1.000 - - - - T 0.39 
CTLA4 rs3087243 204447164 665 1531 0.054 0.70 -0.56 0.48 0.73 A 0.44 
CTLA4 rs1365965 204460115 667 1533 0.167 - - - - C 0.33 
CTLA4 rs3096851 204472127 665 1522 0.288 - - - - C 0.33 
ICOS rs3096851 204472127 665 1522 0.288 - - - - C 0.33 
ICOS rs3116505 204487426 666 1530 0.159 - - - - T 0.33 
ICOS rs3096859 204490820 667 1532 0.148 - - - - C 0.33 
ICOS rs2033171 204496401 667 1531 0.226 - - - - T 0.48 
ICOS rs1978594 204499714 667 1529 0.211 - - - - G 0.48 
ICOS rs3096863 204500977 1125 2563 0.692 - - - - C 0.32 
ICOS rs2352551 204503002 1121 2552 0.611 - - - - T 0.46 































































ICOS rs11889031 204507639 1123 2563 1.000 - - - - T 0.05 
ICOS rs11883722 204509090 1122 2555 0.857 - - - - A 0.20 
ICOS rs4312468 204510350 1124 2561 0.857 - - - - A 0.09 
ICOS rs4675374 204510823 1057 2408 1.000 - - - - T 0.21 
ICOS rs7602383 204514697 1111 2530 1.000 - - - - G 0.13 
ICOS rs4522587 204519868 664 1531 1.000 - - - - G 0.20 
ICOS rs6728120 204527470 667 1530 0.545 - - - - T 0.45 
ICOS rs1559931 204533974 663 1523 0.192 - - - - A 0.25 
ICOS rs4675379 204534340 666 1533 0.643 - - - - C 0.15 
ICOS rs3116534 204542014 662 1522 0.165 - - - - T 0.30 
ICOS rs4675389 204543621 665 1529 0.327 - - - - G 0.38 
ICOS rs933988 204545674 663 1521 0.070 0.41 -0.31 0.01 0.87 G 0.23 
ADAM23 rs10469652 207011064 1096 2435 0.135 - - - - T 0.44 
ADAM23 rs1562660 207013899 728 1776 0.611 - - - - C 0.22 
ADAM23 rs1448903 207017206 1122 2559 0.137 - - - - G 0.09 
ADAM23 rs1448905 207020160 713 1685 0.082 -0.38 -0.08 -0.69 0.46 C 0.41 
ADAM23 rs3755224 207110679 728 1785 0.057 -0.31 -0.22 -0.40 0.69 G 0.13 
ADAM23 rs2300964 207112595 728 1785 0.237 - - - - T 0.05 
ADAM23 rs4675615 207133339 726 1774 0.265 - - - - C 0.30 
ADAM23 rs1013475 207135918 720 1753 0.298 - - - - G 0.21 
ADAM23 rs3770978 207149833 725 1771 0.438 - - - - C 0.16 
ADAM23 rs2276674 207161499 1120 2538 0.356 - - - - T 0.47 
ADAM23 rs3821170 207161555 1113 2536 1.000 - - - - T 0.09 
ADAM23 rs7565709 207166124 1094 2489 0.395 - - - - A 0.26 
ADAM23 rs10497883 207167322 708 1689 0.327 - - - - G 0.19 
ADAM23 rs3732079 207167712 1121 2553 1.000 - - - - T 0.09 
ADAM23 rs10490744 207169528 1113 2535 0.857 - - - - A 0.05 
ADAM23 rs3821172 207173209 1120 2546 0.520 - - - - G 0.16 
ADAM23 rs10490745 207174805 1117 2534 1.000 - - - - T 0.08 
ADAM23 rs4085933 207179129 728 1780 0.571 - - - - C 0.46 
ADAM23 rs1991537 207180818 1120 2539 0.381 - - - - G 0.47 
ADAM23 rs3821173 207186405 1118 2538 0.159 - - - - G 0.49 
ADAM23 rs6732127 207187947 1113 2539 1.000 - - - - T 0.09 
ADAM23 rs3770983 207188853 1117 2531 0.625 - - - - C 0.30 
ADAM23 rs3770984 207190188 1117 2534 0.151 - - - - T 0.48 
ADAM23 rs10186957 207195134 1119 2540 0.340 - - - - C 0.16 
ADAM23 rs10932156 207197675 1121 2544 0.191 - - - - C 0.48 































































ADAM23 rs17786667 207199056 1112 2519 0.424 - - - - C 0.46 
ADAM23 rs2163034 207199871 1117 2529 0.545 - - - - G 0.30 
aLoadings for each trait are reported for SNPs with a multivariate P < 0.1 to guide the identification of 120 
phenotypes contributing to the multivariate result. Loadings correspond to the correlation between each 121 
individual trait and the first canonical variate extracted for the trait set (5). From our experience, traits 122 
with loadings > |0.5| can be interpreted as showing evidence for association. Individual associations 123 
suggested by the multivariate analysis should then be confirmed by univariate approaches. 124 
SNP: single nucleotide polymorphism. Dpter: skin-prick response to house dust mite. FEV1/FVC: forced 125 
expiratory volume in 1 s (FEV1) divided by forced vital capacity (FVC). 126 































































Supplementary Table 4. Univariate association results for the TM study between eosinophil levels and 127 
CD28, CTLA4 and ICOS SNPs on chromosome 2q33. 128 
Gene SNP Position, bp Beta P 
CD28 rs1879877 204278245 -0.013 0.810 
CD28 rs3181096 204278337 -0.106 0.034 
CD28 rs3181098 204278623 -0.116 0.020 
CD28 rs1181388 204284196 0.022 0.750 
CD28 rs3116496 204302757 -0.044 0.450 
CD28 rs3181113 204310155 0.115 0.330 
CD28 rs6435203 204319440 -0.035 0.500 
CD28 rs231385 204329736 -0.035 0.510 
CTLA4 rs231735 204402121 0.014 0.910 
CTLA4 rs926169 204430997 0.006 0.810 
CTLA4 rs231770 204437398 -0.012 0.920 
CTLA4 rs5742909 204440592 -0.005 0.780 
CTLA4 rs231779 204442732 0.022 1.000 
CTLA4 rs3087243 204447164 0.000 0.980 
CTLA4 rs1365965 204460115 0.001 0.700 
CTLA4 rs3096851 204472127 0.019 0.620 
ICOS rs3096851 204472127 0.025 0.620 
ICOS rs3116505 204487426 0.003 0.960 
ICOS rs3096859 204490820 0.001 0.990 
ICOS rs2033171 204496401 0.016 0.750 
ICOS rs1978594 204499714 0.022 0.650 
ICOS rs4522587 204519868 0.042 0.470 
ICOS rs6728120 204527470 -0.063 0.180 
ICOS rs1559931 204533974 -0.115 0.036 
ICOS rs4675379 204534340 -0.123 0.083 
ICOS rs3116534 204542014 0.072 0.170 
ICOS rs4675389 204543621 0.011 0.820 
ICOS rs933988 204545674 0.076 0.170 
ADAM23 rs3732079 207167712 -0.122 0.122 
ADAM23 rs3770984 207190188 -0.046 0.350 
SNP: single nucleotide polymorphism. 129 































































Supplementary Table 5. Univariate association results for the AS study between IgE levels and 130 
ADAMTSL1 SNPs on chromosome 9p21. 131 
SNP Position, bp Beta P 
rs1417037 18461746 -0.03 0.540 
rs2383075 18525581 -0.02 0.750 
rs1889007 18596825 -0.09 0.103 
rs1412671 18628143 -0.05 0.310 
rs1360567 18665325 0.01 0.820 
rs4977340 18708280 -0.01 0.900 
SNP: single nucleotide polymorphism. 132 































































Supplementary Table 6. Multivariate association results for the AS study between MS4A2 SNPs and 133 
Atopy and total IgE levels. 134 
Loadingsa Minor allele SNP Position, bp N families 
N 
individuals P Atopy IgE Allele Freq 
rs2583477 59610431 703 1696 0.097 -0.89 -0.04 C 0.43 
rs1441586 59612604 695 1677 0.019 -0.18 0.77 C 0.43 
rs502581 59616754 703 1698 0.021 -0.16 0.78 T 0.44 
rs502419 59622751 700 1692 0.016 -0.19 0.76 A 0.44 
rs2855017 59622885 703 1700 0.012 -0.29 0.69 T 0.41 
rs17528859 59623955 702 1696 0.018 -0.29 0.69 C 0.41 
aLoadings for each trait are reported to guide the identification of phenotypes contributing to the 135 
multivariate result. Loadings correspond to the correlation between each individual trait and the first 136 
canonical variate extracted for the trait set (5). From our experience, traits with loadings > |0.5| can be 137 
interpreted as showing evidence for association. Individual associations suggested by the multivariate 138 
analysis should then be confirmed by univariate approaches. 139 
SNP: single nucleotide polymorphism. 140 































































Supplementary Table 7. Multivariate association results for the AS study between 20q13 SNPs and six 141 
asthma traits.  142 




ind P Dpter Atopy BHR FEV1 Asthma FEV1/FVC Allele Freq 
CDH26 rs6027217 57981747 696 1360 0.750 - - - - - - A 0.39 
CDH26 rs194990 57992502 695 1359 0.556 - - - - - - G 0.16 
CDH26 rs195001 58006979 687 1341 0.588 - - - - - - T 0.36 
CDH26 rs910695 58021236 688 1346 0.857 - - - - - - C 0.28 
CDH26 rs1576726 58026201 669 1299 0.857 - - - - - - T 0.04 
HRH3 rs6061458 60214968 696 1363 1.000 - - - - - - T 0.28 
HRH3 rs6062144 60215743 696 1366 0.036 -0.910 -0.68 -0.12 -0.20 0.04 0.23 C 0.16 
HRH3 rs1760042 60220455 697 1361 0.524 - - - - - - G 0.18 
HRH3 rs3787429 60224799 695 1360 0.524 - - - - - - A 0.39 
HRH3 rs6587298 60229868 695 1358 1.000 - - - - - - G 0.35 
HRH3 rs1614845 60231063 695 1364 0.857 - - - - - - T 0.19 
HRH3 rs944887 60233194 696 1365 1.000 - - - - - - T 0.19 
HRH3 rs6142998 60236858 689 1345 0.115 - - - - - - A 0.38 
aLoadings for each trait are reported to guide the identification of phenotypes contributing to the 143 
multivariate result. Loadings correspond to the correlation between each individual trait and the first 144 
canonical variate extracted for the trait set (5). From our experience, traits with loadings > |0.5| can be 145 
interpreted as showing evidence for association. Individual associations suggested by the multivariate 146 
analysis should then be confirmed by univariate approaches. 147 
SNP: single nucleotide polymorphism. Dpter: skin-prick response to house dust mite. BHR: bronchial 148 
hyperresponsiveness. FEV1/FVC: forced expiratory volume in 1 s (FEV1) divided by forced vital capacity 149 
(FVC). 150 































































Supplementary Table 8. Gene-gene interaction results for Atopy in the AS study between all eight genes 151 
tested.  152 
Most significant interaction 
Gene 1 Gene 2 
N pairwise 
tests 
performed P SNP1 SNP2 
CD28 CTLA4 135 0.00411 rs6435203 rs3087243 
CD28 ICOS 285 0.00746 rs3116496 rs4675374 
CD28 ADAM23 405 0.04110 rs6435203 rs17786667 
CD28 ADAMTSL1 90 0.02997 rs3116496 rs4977340 
CD28 MS4A2 90 0.12560 rs3181113 rs17528859 
CD28 CDH26 75 0.02188 rs7425641 rs194990 
CD28 HRH3 120 0.02741 rs3181098 rs6142998 
CTLA4 ICOS 170 0.00451 rs3087243 rs4522587 
CTLA4 ADAM23 243 0.01223 rs3087243 rs2300964 
CTLA4 ADAMTSL1 54 0.02668 rs3087243 rs1417037 
CTLA4 MS4A2 54 0.15560 rs1365965 rs1441586 
CTLA4 CDH26 45 0.09339 rs3087243 rs194990 
CTLA4 HRH3 72 0.08781 rs231770 rs6061458 
ICOS ADAM23 513 0.01072 rs6728120 rs3821173 
ICOS ADAMTSL1 114 0.09098 rs4675389 rs1412671 
ICOS MS4A2 114 0.02232 rs3116534 rs2583477 
ICOS CDH26 95 0.02906 rs4675389 rs1576726 
ICOS HRH3 152 0.03159 rs11889031 rs3787429 
ADAM23 ADAMTSL1 162 0.00160 rs3770978 rs1889007 
ADAM23 MS4A2 162 0.02500 rs1562660 rs2583477 
ADAM23 CDH26 135 0.00169 rs3770984 rs6027217 
ADAM23 HRH3 216 0.00059 rs1013475 rs6587298 
ADAMTSL1 MS4A2 36 0.17710 rs1889007 rs17528859 
ADAMTSL1 CDH26 30 0.02937 rs1417037 rs910695 
ADAMTSL1 HRH3 48 0.04545 rs1417037 rs3787429 
MS4A2 CDH26 30 0.09139 rs2583477 rs1576726 
MS4A2 HRH3 48 0.04053 rs502419 rs1760042 
CDH26 HRH3 40 0.05979 rs910695 rs6142998 
SNP: single nucleotide polymorphism.  153 































































Supplementary Table 9. Summary of main results from published candidate-gene association studies of 154 
asthma traits and CD28, CTLA4 and ICOS polymorphisms. 155 
 156 
CD28  CTLA4  ICOS  
Reference  












Nakao et al. 
2000 (6) 
Japanese 120 200 - NS NS NS - Atopic asthma 
Heinzmann et 
al. 2000 (7) 
German 55-189 71-205 - NS NS NS - Asthma, 
atopy, IgE 
levels 
Hizawa et al. 
2001 (8) 
Japanese 339 305 - - NS NS - Asthma, atopy 
  339 - - - 0.005 (C) NS - IgE levels 
  - 305 - - NS NS - IgE levels 
Howard et al. 
2002 (9) 
American 348-359 - NS - NS 0.0005 (A) - IgE levels 
  173-218 129-162 NS - NS 0.012-
0.042 (A) 
- Asthma, BHR, 
atopy 
Lee et al. 
2002 (10) 
Korean 52-88 86-122 - - NS NS - Asthma, 
atopic asthma 
  88 - - - 0.037 (T) NS - Asthma 
severity 
  45 - - - NS 0.019 (G) - BHR 
Bourgain et 
al. 2003 (11) 
Hutterites 261 320 - - 0.013 (T) - - Atopy 
Shilling et al. 
2005 (12) 
Hutterites 71-156 NA - - - - NS Asthma, BHR, 
mold SPT 
  











BHR: bronchial hyperresponsiveness. SPT: skin-prick test. NS: not significant (P > 0.05). NA: not 157 
available. 158 
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